Creative Planning’s Xenon Pharmaceuticals XENE Stock Holding History

Creative Planning’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.5M	Sell	24,805 -5,013	-17%	-$278K	﹤0.01%	2323
2026 Q1	$1.73M	Buy	29,818 +10,618	+55%	+$489K	﹤0.01%	2014
2025 Q4	$861K	Buy	19,200 +5,990	+45%	+$252K	﹤0.01%	2400
2025 Q3	$530K	Buy	+13,210	New	+$465K	﹤0.01%	2661
2015 Q1	–	Sell	-8,000	Closed	-$158K	–	4435
2014 Q4	$158K	Buy	+8,000	New	+$117K	﹤0.01%	1280

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Creative Planning's XENE Position: Q2 2026 in Review

Creative Planning reduced its Xenon Pharmaceuticals (XENE) stake by 17% in Q2 2026, selling an estimated $278K and leaving 24,805 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2323.

Creative Planning first reported a position in XENE in Q4 2014 and has held it in 5 quarters since. The position peaked at $1.73M in Q1 2026. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Creative Planning held 24,805 shares of Xenon Pharmaceuticals worth $1.5M as of Q2 2026.
Creative Planning sold 5,013 Xenon Pharmaceuticals shares in Q2 2026, an estimated $278K.
Xenon Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2323 holding.
Creative Planning first reported a position in Xenon Pharmaceuticals in Q4 2014 and has held it in 5 quarters since.
Creative Planning's Xenon Pharmaceuticals position peaked at $1.73M in Q1 2026.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.